Additionally, TBT modulates angiotensin-II receptor proteins (AT1R and AT2R), the nuclear factor-κB (NF-κB) signaling pathway, and serine/threonine protein kinase (AKT) and ERK expression in abnormal adipocytes, resulting in features of metabolic syndrome (56). Here, AKT1 is linked to metabolic syndrome.